Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity
Authors
Keywords
chimeric antigen receptor, prostate cancer, pancreatic cancer, adoptive cellular immunotherapy, prostate stem cell antigen, immunosuppression, tumor microenvironment, pre-conditioning, cyclophosphamide
Journal
MOLECULAR THERAPY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-02-27
DOI
10.1016/j.ymthe.2021.02.024
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy
- (2020) Patrick Innamarato et al. MOLECULAR THERAPY
- Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors
- (2020) Anthony K. Park et al. Science Translational Medicine
- IFN-γ upregulates membranous and soluble PD-L1 in mesothelioma cells: potential implications for the clinical response to PD-1/PD-L1 blockade
- (2019) Maria Pia Pistillo et al. Cellular & Molecular Immunology
- Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression
- (2019) Sherly Mardiana et al. Science Translational Medicine
- PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity
- (2019) Jianshu Wei et al. Journal for ImmunoTherapy of Cancer
- Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19
- (2019) Mukta Asnani et al. LEUKEMIA
- Intra-arterial Versus Intravenous Adoptive Cell Therapy in a Mouse Tumor Model
- (2018) Anthony Visioni et al. JOURNAL OF IMMUNOTHERAPY
- Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans
- (2018) Marco Ruella et al. MOLECULAR THERAPY
- Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
- (2018) Viktor Fleming et al. Frontiers in Immunology
- Tumor Antigen Escape from CAR T-cell Therapy
- (2018) Robbie G. Majzner et al. Cancer Discovery
- Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma
- (2018) Angela Rita Elia et al. Frontiers in Immunology
- Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models
- (2018) Mo Zhang et al. CLINICAL CANCER RESEARCH
- An immunocompetent mouse model of human glioblastoma
- (2017) Samantha Semenkow et al. Oncotarget
- Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer
- (2017) Saul J. Priceman et al. OncoImmunology
- Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy
- (2017) Gail D. Sckisel et al. Journal for ImmunoTherapy of Cancer
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
- (2016) Meenakshi Hegde et al. JOURNAL OF CLINICAL INVESTIGATION
- T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
- (2016) E. Zah et al. Cancer Immunology Research
- Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome
- (2016) Linan Wang et al. OncoImmunology
- Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
- (2015) Soranobu Ninomiya et al. BLOOD
- Smart CARs engineered for cancer immunotherapy
- (2015) Saul J. Priceman et al. CURRENT OPINION IN ONCOLOGY
- The Molecular Signatures Database Hallmark Gene Set Collection
- (2015) Arthur Liberzon et al. Cell Systems
- HTSeq--a Python framework to work with high-throughput sequencing data
- (2014) S. Anders et al. BIOINFORMATICS
- Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen-Specific Regulatory T Cells
- (2014) Dan Blat et al. MOLECULAR THERAPY
- Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
- (2013) L Bracci et al. CELL DEATH AND DIFFERENTIATION
- Cyclophosphamide Induces a Type I Interferon-Associated Sterile Inflammatory Response Signature in Cancer Patients' Blood Cells: Implications for Cancer Chemoimmunotherapy
- (2013) F. Moschella et al. CLINICAL CANCER RESEARCH
- Software for Computing and Annotating Genomic Ranges
- (2013) Michael Lawrence et al. PLoS Computational Biology
- TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions
- (2013) Daehwan Kim et al. GENOME BIOLOGY
- Cyclophosphamide-induced Myeloid-derived Suppressor Cell Population Is Immunosuppressive But Not Identical to Myeloid-derived Suppressor Cells Induced By Growing TC-1 Tumors
- (2012) Romana Mikyšková et al. JOURNAL OF IMMUNOTHERAPY
- Engineered Tcells for pancreatic cancer treatment
- (2011) Usha L. Katari et al. HPB
- Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
- (2010) J. N. Kochenderfer et al. BLOOD
- Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis
- (2010) G. Schiavoni et al. CANCER RESEARCH
- Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination
- (2009) Vedran Radojcic et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Mapping and quantifying mammalian transcriptomes by RNA-Seq
- (2008) Ali Mortazavi et al. NATURE METHODS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started